Clinical pharmacokinetics of non-steroidal anti-inflammatory drugs

Clinical Pharmacokinetics
R K VerbeeckG R Loewen

Abstract

The number of non-steroidal anti-inflammatory drugs (NSAIDs) available for clinical use has dramatically increased during the last decade. As a general rule, NSAIDs are well absorbed from the gastrointestinal tract, with the exception of aspirin (and possibly diclofenac, tolfenamic acid and fenbufen) which undergoes presystemic hydrolysis to form salicylic acid. Concomitant administration of NSAIDs with food or antacids may in some cases lead to delayed or even reduced absorption. The NSAIDs are highly bound to plasma proteins (mainly albumin), which limits their body distribution to the extracellular spaces. Apparent volumes of distribution of NSAIDs are, therefore, very low and usually less than 0.2 L/kg. The elimination of these drugs depends largely on hepatic biotransformation; renal excretion of unchanged drugs is usually small (less than 5% of the dose). Total body clearance is low and for most NSAIDs is less than 200 ml/min. The effect of age and disease on the disposition of NSAIDs has not been extensively studied. Due to the central role of the liver in the overall elimination of the majority of these compounds, hepatic disease will most likely lead to a significant alteration in their pharmacokinetic behaviour. NSAID...Continue Reading

Citations

Jan 1, 1988·European Journal of Clinical Pharmacology·B BannwarthR J Royer
Jan 1, 1985·European Journal of Clinical Pharmacology·A DarraghE Casey
Jan 1, 1985·European Journal of Clinical Pharmacology·P NetterR J Royer
Jan 1, 1985·European Journal of Clinical Pharmacology·E Zylber-KatzM Levy
Jan 1, 1987·European Journal of Clinical Pharmacology·C J RichardsonR K Verbeeck
Jan 1, 1983·European Journal of Clinical Pharmacology·R K Verbeeck, S M Wallace
Jan 1, 1986·European Journal of Clinical Pharmacology·F F HorberF J Frey
Jan 1, 1990·Archives of Toxicology·K McCormack, K Brune
Jul 1, 1994·European Journal of Drug Metabolism and Pharmacokinetics·D A Smith
Jan 1, 1997·European Journal of Clinical Pharmacology·D TürckJ Hoffmann
Mar 21, 2007·Pharmaceutical Research·Trudy Rodgers, Malcolm Rowland
Jul 2, 1999·The American Journal of Medicine·A I Schafer
Sep 10, 1998·Journal of Veterinary Pharmacology and Therapeutics·E VinagreT Encinas
Jan 29, 2000·Journal of Veterinary Pharmacology and Therapeutics·M F LandoniP Lees
Jul 10, 2001·Journal of Veterinary Pharmacology and Therapeutics·C R VerdeM F Landoni
Jul 12, 2007·Pharmacogenetics and Genomics·Yu ChenJohanna W Lampe
Aug 1, 1990·British Journal of Clinical Pharmacology·D HartmannW K Waldhäusl
Oct 1, 1994·British Journal of Clinical Pharmacology·S G OwenM S Roberts
Apr 1, 1995·Journal of Clinical Pharmacy and Therapeutics·A M TaburetE Leutenegger
Jul 18, 2001·Biological & Pharmaceutical Bulletin·H EndoS Higuchi
Mar 3, 2007·American Journal of Veterinary Research·Olivia J InoueRobert B Clarkson
Dec 18, 2013·European Journal of Pharmaceutical Sciences : Official Journal of the European Federation for Pharmaceutical Sciences·Dustin L CooperSam Harirforoosh
Jan 1, 1989·European Journal of Clinical Pharmacology·A Van HeckenP J De Schepper
Jan 1, 1988·European Journal of Clinical Pharmacology·R K VerbeeckP Le Morvan
Oct 17, 2009·Expert Opinion on Drug Safety·Sam Harirforoosh, F Jamali
Mar 11, 1999·Drug Development and Industrial Pharmacy·M D HussainG K Vudathala
Jan 1, 1995·Critical Reviews in Toxicology·U A BoelsterliA Kretz-Rommel
Jan 1, 1988·Scandinavian Journal of Rheumatology. Supplement·A Bjelle
Jan 1, 1989·Scandinavian Journal of Rheumatology. Supplement·M Schmitt, T W Guentert
Jan 1, 1988·Scandinavian Journal of Rheumatology. Supplement·E AlbengresJ P Tillement
Jan 1, 1988·Journal of Pharmaceutical Sciences·R T FosterS R Alballa
Jan 1, 1991·Chirality·J OravcováT Trnovec
Feb 1, 1997·The American Journal of Medicine·D H Solomon, J H Gurwitz
Nov 18, 2014·European Journal of Clinical Investigation·Eva-Luise HoblBernd Jilma
Sep 17, 2005·Journal of Clinical Pharmacy and Therapeutics·L ChungT M Bush
Jan 19, 2011·British Journal of Clinical Pharmacology·Martin BrunnerMarkus Müller
Jul 13, 1984·The American Journal of Medicine·K S AlbertG F Lockwood
Oct 30, 1987·The American Journal of Medicine·F G McMahonD A Fitts
Oct 1, 1991·Seminars in Arthritis and Rheumatism·D S Newcombe
Nov 1, 1984·British Journal of Clinical Pharmacology·S GeorgeJ Ward
Feb 1, 1985·British Journal of Clinical Pharmacology·K StoeckelU Hennes
Mar 1, 1985·British Journal of Clinical Pharmacology·D J GreenblattR I Shader
Dec 1, 1988·Journal of Clinical Pharmacology·P ChaikinH S Weintraub
Jun 1, 1988·Journal of Clinical Pharmacology·D C Brater
Jul 4, 2006·Prostaglandins, Leukotrienes, and Essential Fatty Acids·M SugimotoS Nakaike
Jun 24, 2006·Atherosclerosis·Nalini Santanam, Sampath Parthasarathy
Mar 10, 2005·The Medical Clinics of North America·Steven Gabardi, Stuart Abramson
Feb 1, 1990·Xenobiotica; the Fate of Foreign Compounds in Biological Systems·M MishimaC Yamato
Dec 25, 2010·Xenobiotica; the Fate of Foreign Compounds in Biological Systems·Chao ZhangWei Wang
Apr 10, 2014·Journal of Traditional and Complementary Medicine·Ming-Chen ChenJung-Der Wang
Jan 1, 1992·International Orthopaedics·H J ReisT Schellinger
Aug 9, 1993·The American Journal of Medicine·D E HillemanB D Lucas
Mar 1, 1997·Clinical Pharmacology and Therapeutics·J C ErmerR M Cohen
Mar 10, 2017·Xenobiotica; the Fate of Foreign Compounds in Biological Systems·Sara BounaktaSami Haddad
Jul 20, 2018·Animals : an Open Access Journal From MDPI·Shashwati MathurkarPaul Chambers
Aug 1, 1994·Biopharmaceutics & Drug Disposition·M A al-MeshalM W Gouda
Apr 1, 1995·Biopharmaceutics & Drug Disposition·E SamaraM Bialer
Apr 1, 1990·Biopharmaceutics & Drug Disposition·L K Roskos, F D Boudinot
May 1, 1996·Clinical and Experimental Pharmacology & Physiology·S L ElliottN D Yeomans
Mar 19, 2014·Chemical Society Reviews·Ignacio VayáMiguel A Miranda
Dec 1, 1992·The Journal of Laryngology and Otology·S Kristensen
Jun 1, 1984·British Journal of Clinical Pharmacology·R K VerbeeckG R Loewen
Jan 22, 2020·International Journal of Clinical Pharmacy·Wen Yea HwongSheamini Sivasampu
Sep 1, 1984·Arthritis and Rheumatism·D J GreenblattR I Shader
May 1, 1986·Acta Pharmacologica Et Toxicologica·E VingeE Arnold
Oct 1, 1985·Arthritis and Rheumatism·D R Abernethy, D J Greenblatt
Jul 1, 1985·Drug Intelligence & Clinical Pharmacy·R S RhodesC D Sintek
Jul 1, 1987·Drug Intelligence & Clinical Pharmacy·P F D'Arcy, J C McElnay
Oct 27, 2020·Frontiers in Veterinary Science·Rochelle WarnerPatrick J Gorden
May 30, 2020·Journal of Medicinal Chemistry·Mateusz P CzubWladek Minor
Apr 25, 2009·The Journal of Physical Chemistry. B·Carlos J BuenoMiguel A Miranda
Jan 1, 1985·Journal of Pharmaceutical and Biomedical Analysis·P Miskolczi, L Vereczkey

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Hereditary Sensory Autonomic Neuropathy

Hereditary Sensory Autonomic Neuropathies are a group of inherited neurodegenerative disorders characterized clinically by loss of sensation and autonomic dysfunction. Here is the latest research on these neuropathies.

Spatio-Temporal Regulation of DNA Repair

DNA repair is a complex process regulated by several different classes of enzymes, including ligases, endonucleases, and polymerases. This feed focuses on the spatial and temporal regulation that accompanies DNA damage signaling and repair enzymes and processes.

Glut1 Deficiency

Glut1 deficiency, an autosomal dominant, genetic metabolic disorder associated with a deficiency of GLUT1, the protein that transports glucose across the blood brain barrier, is characterized by mental and motor developmental delays and infantile seizures. Follow the latest research on Glut1 deficiency with this feed.

Separation Anxiety

Separation anxiety is a type of anxiety disorder that involves excessive distress and anxiety with separation. This may include separation from places or people to which they have a strong emotional connection with. It often affects children more than adults. Here is the latest research on separation anxiety.

KIF1A Associated Neurological Disorder

KIF1A associated neurological disorder (KAND) is a rare neurodegenerative condition caused by mutations in the KIF1A gene. KAND may present with a wide range and severity of symptoms including stiff or weak leg muscles, low muscle tone, a lack of muscle coordination and balance, and intellectual disability. Find the latest research on KAND here.

Regulation of Vocal-Motor Plasticity

Dopaminergic projections to the basal ganglia and nucleus accumbens shape the learning and plasticity of motivated behaviors across species including the regulation of vocal-motor plasticity and performance in songbirds. Discover the latest research on the regulation of vocal-motor plasticity here.

Related Papers

Thrombosis Research. Supplement
J J Thiessen
Inflammation Research : Official Journal of the European Histamine Research Society ... [et Al.]
A MukherjeeR Stein
© 2021 Meta ULC. All rights reserved